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Abstract
Background: Numerous epidemiological studies have examined associations of genetic variations in LEP (G2548A,
-2548 nucleotide upstream of the ATG start site) and LEPR (Q223R, nonsynonymous SNP in exon 6) with cancer
susceptibility; however, the findings are inconsistent. Therefore, we performed a meta-analysis to comprehensively
evaluate such associations.
Methods: We searched published literature from MEDLINE, EMBASE, Web of Science and CBM for eligible
publications. We also assessed genotype-based mRNA expression data from HapMap for rs7799039 (G2548A) and
rs1137101 (Q223R) in normal cell lines derived from 270 subjects with different ethnicities.
Results: The final analysis included 16 published studies of 6569 cases and 8405 controls for the LEP G2548A and
19 studies of 7504 cases and 9581 controls for the LEPR Q223R. Overall, LEP G2548A was statistically significantly
associated with an increased risk of overall cancer (AA vs. GG: OR=1.27, 95% CI=1.05-1.54; recessive model:
OR=1.19, 95% CI=1.00-1.41). Further stratifications by cancer type showed an increased risk for prostate cancer
(recessive model: OR=1.26, 95% CI=1.05-1.51) but not for other cancers. For LEPR Q223R, no statistical evidence
for an association with risk of cancer was found for all; however, further stratification by ethnicity showed an
increased risk for Africans but not for other ethnicities. No significantly differences in LEP and LEPR mRNA
expression were found among genotypes or by ethnicity.
Conclusions: Despite some limitations, this meta-analysis found some statistical evidence for an association
between the LEP 2548AA genotype and overall risk of cancer, particularly for prostate cancer, but given this variant
did not have an effect on mRNA expression, this association warrants additional validation in large and well-designed
studies.
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Introduction
Cancer is recognized as one of the leading causes of death
in economically developed countries as well as in developing
countries. With the estimated 12.7 millions of cancer cases and
7.6 millions of cancer deaths occurred in 2008, cancer has
become a major public health challenge [1]. Because of the
combination of earlier detection and improved treatment, the
overall cancer mortality is decreasing over the last decade.
However, the global burden of cancer continues to increase,
largely due to the increased longevity and subsequent growth
of the world populations that increasingly adopt cancer-causing
behaviors [1]. While the mechanism of carcinogenesis is still
not fully understood, it has been suggested that environmental
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factors, interplaying with low-penetrance susceptibility genes,
may be important in the development of cancer [2,3].
Leptin (LEP, also called OB for obese), an adipocyte-derived
hormone, produced predominantly by white adipose tissue,
regulates appetite and weight, body metabolism and
reproductive functions together with the leptin receptor (LEPR)
(Figure 1) [4]. The LEP gene, located at chromosome 7q31.3,
encodes a 16 kDa protein that has been consistently shown to
be associated with endocrinologic metabolism [5]. It has been
also suggested that leptin could contribute to serum insulin
levels and the development of type 2 diabetes [6] and that
leptin is involved in the pathophysiology of obesity [7,8] and
carcinogenesis [9-14]. Leptin exerts its physiological action
through its receptor (LEPR, also called CD295, and its gene is
located at chromosome 1p31), which is a single
transmembrane protein distributed in many types of tissues
[15].
LEP and LEPR are highly polymorphic, and a number of
single nucleotide polymorphisms (SNPs) have been identified
in these two genes [6,8,16,17]. For example, there are at least
383 reported SNPs in the LEP gene region and 3117 reported
SNPs in the LEPR gene region (http://www.ncbi.nlm.nih.gov/
projects/SNP). However, only few of these reported SNPs are
potentially functional and ever studied for their associations
with cancer susceptibility. For LEP, there are two SNPs that
reportedly change amino acid of the protein but only G2548A
(rs7799039) was extensively investigated for its association
with cancer risk; for LEPR, there are five common (minor allele
frequency > 0.05) SNPs that may cause amino acid changes,
but only Q223R (rs1137101) was studied for its association
with cancer susceptibility. Because the results from these
studies are inconsistent [9-14,16,18-40], we performed a meta-
analysis of the published reports to further evaluate the
association of these two SNPs with the risk of cancer.
Figure 1.  Gene structural characteristics of leptin and leptin receptor and their roles in regulating adipose tissue
mass.  The locations of LEP G2548A (A) and LEPR Q223R (B) with possible leptin functions and the pathway of regulating adipose
tissue mass (C).
doi: 10.1371/journal.pone.0075135.g001
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Materials and Methods
Identification and eligibility of relevant studies
Published studies were included, if they met the following
three inclusion criteria: (a) evaluating the association between
LEP G2548A (or A19G) and/or LEPR Q223R SNPs and cancer
risk, (b) using a case-control design, (c) providing sufficient
data for calculation of an odds ratio (OR) with 95% confidence
interval (CI).
We searched electronic literature MEDLINE, EMBASE, Web
of Science and Chinese Biomedical (CBM) (http://
www.imicams.ac.cn) databases for all relevant articles using
the search terms: “leptin or LEP”, “leptin receptor gene or
LEPR”, “variant, variation or polymorphism” and “cancer,
carcinoma or tumor” (the last search was updated on March
10, 2013). All eligible studies were retrieved, and their
bibliographies were manually checked for other relevant
publications. Review articles and bibliographies of other
relevant studies identified were hand-searched as well to find
additional eligible studies. Only published studies with full-text
articles in English or Chinese were included. If more than one
article was published using the same patient population, only
the latest or the largest study was used in this meta-analysis.
Two authors independently assessed the articles for
compliance with the inclusion criteria, and disagreement was
resolved by discussions until the consensus was reached.
Data extraction
The following information was collected from each study: first
author's surname, publication date, ethnicity of the study
population, cancer type, source used for controls, total number
of cases and controls, and numbers of cases and controls with
the AA, AG and GG genotypes for LEP G2548A and LEPR
Q223R, respectively.
Genotype and gene expression correlation analysis
The data on LEP and LEPR genotype and transcript (mRNA)
expression levels were available online (http://app3.titan.uio.no/
biotools/help.php?app=snpexp) [41]. The genotyping data were
derived from The HapMap phase II release 23 data set
consisting of 3.96 million SNP genotypes from 270 individuals
from four populations (CEU: 90 Utah residents with ancestry
from northern and western Europe; CHB: 45 unrelated Han
Chinese in Beijing; JPT: 45 unrelated Japanese in Tokyo; YRI:
90 Yoruba in Ibadan, Nigeria) [42,43]. The transcript (mRNA)
expression data by genotypes were from EBV-transformed B
lymphoblastoid cell lines from the same 270 individuals [44,45].
Statistical methods
The strength of associations of LEP G2548A and LEPR
Q223R SNPs with cancer risk was assessed by calculating
ORs with the corresponding 95% CIs. For LEP G2548A, the
pooled ORs were performed for homozygous model (AA vs.
GG), heterozygous model (AG vs. GG), recessive model (AA
vs. AG+GG), and dominant model (AA+AG vs. GG). For LEPR
Q223R, the pooled ORs were also performed for homozygous
model (GG vs. AA), heterozygous model (AG vs. AA),
recessive model (GG vs. AG+AA), and dominant model (GG
+AG vs. AA). The homogeneity assumption was verified by
using a Chi square-based Q-test. If the studies were found to
be homogeneous (with P>0.10 for the Q test), the pooled OR
estimate of all studies was calculated by the fixed-effects
model (the Mantel–Haenszel method) [46]. If homogeneity
could not be assumed, a random-effects model (the
DerSimonian and Laird method) was used [47]. Subgroup
analyses were performed by cancer type, ethnicity, study
design and sample size (i.e., no. of cases ≥150 vs. no. of cases
<150). To verify the presence of potential publication bias, a
standard error of log (OR) for each study was plotted against
its log (OR). Funnel plot asymmetry was assessed by Egger’s
linear regression test [48]. To assess the effect of individual
studies on the overall risk of cancers, sensitivity analyses were
performed by excluding each study individually and
recalculating the ORs and 95% CI. The mRNA expression
levels between the strata were assessed by using a Student’s t
test, and the trend tests of transcript expression levels by
genotypes were evaluated by using General linear model. This
meta-analysis was performed using the software STATA
version 10.0 (Stata Corporation, College Station, TX) and SAS
software (version 9.1; SAS Institute, Cary, NC). All P values




As shown in Figure 2, a total of 115 published records were
retrieved, of which 85 were excluded after the abstracts were
found to be irrelevant, and three papers were excluded, for two
[49,50] of which were covered by another study [11], and one
was written in Russian [26]. Finally, 27 papers met the
inclusion criteria and were included in the meta-analysis (Table
1). Overall, 16 studies with 6569 cases and 8405 controls
investigated the LEP G2548A (or A19G) SNP, and another 19
studies with 7504 cases and 9581 controls investigated the
LEPR Q223R SNP. The study of Teras et al. [29] on the two
SNP was included only in the calculation of the dominant
model, because the genotype distribution was not presented in
enough detail.
Meta-analysis results
The overall results suggested a statistically significant
association between LEP G2548A (or A19G) and risk of cancer
(AA vs. GG: OR=1.27, 95% CI=1.05-1.54; AA vs. AG+GG:
OR=1.19, 95% CI=1.00-1.41) (Table 2, Figure 3). In the
subgroup analysis by ethnicity, a statistically significant
association was found for Caucasians (AA vs. GG: OR=1.24,
95% CI=1.01-1.53; recessive model: OR=1.23, 95%
CI=1.01-1.51) and Africans (AA vs. GG: OR=3.17, 95%
CI=1.54-6.51; recessive model: OR=2.62, 95% CI=1.31-5.26)
but not for other ethnic groups. In the subgroup analysis by
tumor type, the LEP 2548A (or 19G) allele was significantly
associated with risk of prostate cancer (AA vs. AG+GG:
OR=1.26, 95%CI=1.05-1.51) but not with cancers of the
breasts and colorectal or other specified cancers. In the
LEP and LEPR Variants with Cancer Susceptibility
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subgroup analysis by sample size, a statistically significant
association was found for studies with sample sizes <150 (AA
vs. GG: OR=1.78, 95% CI=1.24-2.54; AA vs. AG+GG:
OR=1.33, 95% CI=1.00-1.78) but not for those with sample
sizes ≥150.
For the LEPR Q223R SNP, no statistically significant
association with cancer risk was found (Table 3, Figure 4). In
the stratified analysis by ethnicity, however, a statistically
significant association was observed for Africans (GG vs. AA:
OR=1.85, 95% CI=1.23-2.79; GA vs. AA: OR=1.48, 95%
CI=1.08-2.01; GG vs. GA+AA: OR=1.48, 95% CI=1.07-2.05;
GG+GA vs. AA: OR=1.58, 95% CI=1.14-2.20), but not for
Caucasians and other ethnic populations. No statistically
significant association was found in the further stratification by
tumor type, source of controls, and sample size.
The mRNA expression by genotypes
The mRNA expression levels of LEP and LEPR by the
genotypes for four ethnicities are shown in Table 4. We did not
find any differences in mRNA expression by genotypes among
different ethnicities. No trend of transcript expression levels by
genotypes was found for LEP or LEPR. These data suggest
that the variants under investigation may not have a significant
effect on gene expression, at least at mRNA levels.
Publication bias
For LEP G2548A (or A19G), there was evidence for
publication bias under a homozygous additive model (the
Egger’s test: AA vs. GG: P=0.034); however, this was not
observed under other genetic models (AG vs. GG: P=0.174;
recessive model: P=0.138; dominant model: P=0.071). The
publication bias may be ascribed to small sample sizes the
included studies had. When studies with cases smaller than
150 in numbers were excluded, the publication bias
disappeared, but the significant association also disappeared.
No publication bias was detected for LEPR Q223R (the
Egger’s test: GG vs. AA: P=0.559, AG vs. AA: P=0.686,
recessive model: P=0.600, dominant model: P=0.600).
Discussion
It is well recognized that individual susceptibility to cancer
varies, even with the same environmental exposure. Therefore,
a role for genetic variation, such as SNPs of genes involved in
Figure 2.  Flow chart of included studies for this meta-analysis.  
doi: 10.1371/journal.pone.0075135.g002
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carcinogenesis, has been suggested. Epidemiological studies
have shown that overweight and obesity might be associated
with an increased risk of cardiovascular disease and type II
diabetes; moreover, excessive body weight has been directly
associated with risk of cancer at several organ sites, including
the colon, breasts (in postmenopausal women), endometrium,
esophagus, and kidney [51]. Formerly, immune dysfunction has
been shown to be associated with obesity [20], whereas leptin
concentrations were recently found to be higher in Africans,
compared with Caucasians, after adjustment for BMI and other
factors [52].
The Q223R SNP (but not the K109R or K656N SNPs) of the
LEPR gene has been reported to be associated with obesity
and to predict a small percentage of body weight and body
composition variability in a genetically homogeneous
population [8]. Previous reports demonstrated that genetic
variation in LEPR affected cancer susceptibility with
significantly higher frequency of the LEPR 223Arg allele in
patients than in controls [9,11,22,24,33]; however, this
association was not be replicated by later studies
[14,16,19,23,31,36]. Likewise, previous reports also
demonstrated that LEP 2548AA was associated with an
increased risk of cancer [12,13,20,21,33,34]; however,
replication of this finding by others also failed as well
[25,28,31].
In this meta-analysis, we found statistical evidence for a
significant but week association of cancer risk with the LEP
G2548A (or A19G) SNP but not with the LEPR Q223R SNP.
There are several biologically plausible explanations for this
finding. Firstly, it has been described that genetic variants in
the promoter region of LEP can influence leptin expression,
possibly at the transcriptional level, thereby altering adipose
secretion levels of the hormone [17]. Additionally, it is also
likely that the observed association may be due to improved
study power from pooling studies with small sample sizes that
separately may have had insufficient statistical power to detect
a weak effect. Thus, in the genotype-based mRNA expression
analysis using data from HapMap for the LEP G2548A, we did
not find statistical difference may be ascribed to small sample
size for each ethnicity or the G2548A may have a weak effect.
In the subgroup analysis by tumor type, an observed
association between LEP 2548A (or 19G) and risk of prostate
cancer suggests that this SNP may be disease specific,
because all the prostate cancer patients were Caucasian
decent. In the subgroup analysis by sample size, we found that
the association between studies with small sample sizes and
Table 1. Characteristics of studies included in the meta-analysis.
Surname Year Country Ethnicity Cancer type cases/controls Source of controls Genotype method Polymorphisms
Kote-Jarai 2003 UK Caucasian Prostate cancer 273/262 PB* PCR-RFLP Q223R
Ribeiro 2004 Portugal Caucasian Prostate cancer 143/118 HB PCR-RFLP G2548A
Ribeiro 2006 Portugal Caucasian Lung cancer 102/342 HB PCR-RFLP G2548A
Woo 2006 Korea Asian Breast cancer 45/45 HB PCR-sequencing Q223R
Snoussi 2006 Tunisia African Breast cancer 308/222 HB PCR-RFLP G2548A, Q223R
Gallicchio 2007 USA Caucasian Breast cancer 53/872 PB TaqMan Q223R
Han 2008 China Asian Breast cancer 240/500 HB PCR-RFLP Q223R
Okobia 2008 Nigeria African Breast cancer 209/209 HB PCR-RFLP Q223R
Ulybina 2008 Russia Caucasian Breast cancer 110/105 HB Real-time PCR Q223R
Slattery 2008 USA Mixed Colorectal cancer 1565/1965 Mixed TaqMan G2548A
Doecke 2008 Australia Caucasian Esophageal cancer 261/1352 PB Sequenom iPLEX G2548A, Q223R
Ulybina 2008 Russia Caucasian Endometrial cancer 191/105 HB Real-time PCR Q223R
Teras 2009 USA Caucasian Breast cancer 641/650 PB SNPstream G2548A, Q223R
Moore 2009 Finland Caucasian Prostate cancer 947/863 PB TaqMan G2548A
Wang 2009 USA Caucasian Prostate cancer 253/257 PB TaqMan G2548A
Yapijakis 2009 Greece & Germany Caucasian Oral cancer 150/152 HB PCR-RFLP G2548A, Q223R
Pechlivanis 2009 Czech Caucasian Colorectal cancer 659/711 HB TaqMan G2548A, Q223R
Vašků 2009 Czech Caucasian Colorectal cancer 100/100 HB PCR-sequencing G2548A, Q223R
Tsilidis 2009 USA Mixed Colorectal cancer 204/362 PB TaqMan G2548A
Chovanec 2009 Czech Caucasian Endometrial cancer 66/66 HB Unknown G2548A
Cleveland 2010 USA Caucasian Breast cancer 1059/1101 PB Unknown G2548A, Q223R
Partida-Perez 2010 Mexico Latin American Colorectal cancer 68/102 HB PCR-RFLP G2548A
Dai 2010 China Asian Hepatocellular 82/102 HB PCR-RFLP Q223R
Nyante 2011 USA Mixed Breast cancer 1972/1775 PB Illumina Q223R
Kim 2012 Korea Asian Breast cancer 390/447 HB MassARRAY Q223R
Li 2012 China Asian Lung cancer 744/832 PB PCR-RFLP Q223R
Kim 2012 Korea Asian Gastric cancer 48/48 HB PCR-RFLP G2548A, Q223R
Notes: LEP G2548A is in high linkage disequilibrium with A19G; * Spouses of patients with CRC.
HB, Hospital based; PB, Population based; RFLP, Restriction fragment length polymorphisms polymerase chain reaction.
doi: 10.1371/journal.pone.0075135.t001
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cancer risk for the G2548A polymorphism may be ascribed to
some selection bias. In contrast to another meta-analysis,
however, we were not able to find a statistically significant
association between LEPR Q223R and risk of breast cancer
[53]. This could be explained by the fact that we included a
latest study on breast cancer that included 1972 cases and
1775 controls, a null study that was not included in the previous
meta-analysis.
In exploring possible functional relevance of the SNPs under
investigation, we did not find any differences in or trends of the
mRNA expression levels of LEP and LEPR by their genotypes
in four ethnic groups. Cancer is a complex and multifactorial
disease, and gene-gene and gene-environment interactions
may contribute greatly to its occurrence, but a single nucleotide
alteration may be insufficient to alter the mRNA expression,
even for those SNPs in the coding regions that may lead to
amino acid change or the polymorphisms in a promoter may
have a subtle, potential effect on the gene expression.
Though we performed this meta-analysis using the pooled
data that can yield more reliable or statistically more powerful
results, several limitations should be addressed. First,
significant heterogeneity were found for both of these two
polymorphisms that may influence the interpretation of the
results. Second, the individual sample sizes for cases of most
studies included in the analysis were relatively small (<500)
except for seven studies [25,27-29,34,36,39], and there were
only one study based on the population of Latin Americans,
Africans and Asians for the G2548A polymorphism,
respectively, which did not provide insufficient statistical power
to investigate the real association. Third, most of the studies
used hospital-based controls that may result in some selection
biases. Finally, the lacking of original data such as age, sex,
smoking and drinking status, BMI, environmental factors and
other lifestyle, limited our ability to further evaluate of gene-
gene and gene-environment interactions.
In conclusion, this meta-analysis found that the LEP 2548AA
genotype was associated with a weakly increased risk of
cancer, mainly for prostate cancer, while LEPR Q223R was
not. However, given the relatively limited sample sizes and the
lack of detailed information, this analysis with mixed ethnicities
was not able to address cancer outcomes and biological
evidence for genotype-phenotype (mRNA expression)
correlations. It is clear that further studies are warranted to
validate the association between the LEP G2548A
polymorphism and cancer risk.
Table 2. Meta-analysis of the association between LEP G2548A polymorphism and cancer risk.
Variables No. of studiesa Homozygous co-dominant Phetb Heterozygous co-dominant Phetb Recessive Phetb Dominant Phetb
  AA vs. GG  AG vs. GG  (AA vs. AG+GG)  (AA+AG vs. GG)  
All 15 1.27 (1.05-1.54) 0.003 1.04 (0.96-1.13) 0.154 1.19 (1.00-1.41) 0.000 1.08 (0.97-1.20) 0.089
Cancer type          
Breast 2 1.91 (0.82-4.45) 0.025 1.02 (0.86-1.21) 0.033 1.74 (0.96-3.17) 0.088 1.12 (0.85-1.46) 0.030
Colorectal 5 0.97 (0.78-1.20) 0.216 1.03 (0.92-1.17) 0.188 0.92 (0.81-1.05) 0.532 1.02 (0.84-1.23) 0.160
Prostate 3 1.42 (0.94-2.12) 0.138 1.13 (0.94-1.36) 0.068 1.26 (1.05-1.51) 0.501 1.30 (0.92-1.84) 0.060
Others 5 1.32 (0.91-1.92) 0.270 0.96 (0.74-1.24) 0.736 1.27 (0.79-2.08) 0.004 1.02 (0.80-1.32) 0.952
Ethnicity          
Caucasian 10 1.24 (1.01-1.53) 0.036 0.99 (0.89-1.10) 0.333 1.23 (1.01-1.51) 0.003 1.03 (0.93-1.15) 0.299
Latin American 1 2.53 (0.89-7.18) / 2.97 (1.17-7.50) / 1.08 (0.53-2.21) / 2.83 (1.15-6.98) /
African 1 3.17 (1.54-6.51) / 1.45 (1.01-2.07) / 2.62 (1.31-5.26) / 1.62 (1.14-2.29) /
Asian 1 0.88 (0.05-14.69)  1.29 (0.07-22.42)  0.69 (0.30-1.61)  1.00 (0.06-16.46) /
Mixed 2 0.94 (0.79-1.13) 0.455 1.05 (0.91-1.22) 0.796 0.96 (0.76-1.19) 0.213 1.02 (0.89-1.17) 0.899
Source of controls          
Hospital 9 1.70 (1.10-2.61) 0.002 1.10 (0.94-1.29) 0.028 1.39 (0.99-1.95) 0.003 1.28 (0.97-1.69) 0.011
Population 5 1.22 (1.05-1.41) 0.604 0.99 (0.88-1.13) 0.894 1.15 (0.95-1.38) 0.074 1.03 (0.93-1.15) 0.923
Mixed 1 0.92 (0.76-1.11) / 1.06 (0.91-1.23) / 0.89 (0.75-1.05) / 1.02 (0.88-1.17) /
Sample size in cases          
< 150 6 1.78 (1.24-2.54) 0.677 1.29 (0.98-1.71) 0.060 1.33 (1.00-1.78) 0.397 1.44 (0.98-2.13) 0.120
>=150 9 1.16 (0.95-1.43) 0.003 1.02 (0.94-1.11) 0.588 1.16 (0.95-1.41) 0.000 1.03 (0.95-1.12) 0.360
a Only presented the study with enough detail, one study was included only in the calculation of the dominant model.
b P value of the Q-test for heterogeneity test.
doi: 10.1371/journal.pone.0075135.t002
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Figure 3.  Forest plot for AA vs. GG of LEP G2548A polymorphism.  
doi: 10.1371/journal.pone.0075135.g003
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Table 3. Meta-analysis of the association between LEPR Q223R polymorphism and cancer risk.
Variables No. of studiesa Homozygous co-dominant Phetb Heterozygous co-dominant Phetb Recessive Phetb Dominant Phetb
  GG vs. AA  AG vs. AA  (GG vs. AG+AA)  (GG+AG vs. AA)  
All 18 1.02 (0.76-1.39) 0.000 1.08 (0.88-1.34) 0.000 0.98 (0.82-1.18) 0.000 1.03 (0.83-1.29) 0.000
Cancer type          
Breast 9 0.94 (0.62-1.42) 0.000 0.97 (0.72-1.31) 0.000 0.95 (0.76-1.20) 0.000 0.93 (0.70-1.24) 0.000
Colorectal 2 1.15 (0.86-1.53) 0.507 1.25 (0.70-2.23) 0.090 1.09 (0.85-1.39) 0.789 1.23 (0.76-1.98) 0.130
Prostate 1 0.82 (0.52-1.29) / 0.85 (0.58-1.26) / 0.89 (0.59-1.34) / 0.84 (0.59-1.19) /
Others 6 1.09 (0.49-2.39) 0.000 1.27 (0.83-1.94) 0.029 1.04 (0.62-1.75) 0.000 1.17 (0.90-1.96) 0.000
Ethnicity          
Caucasian 9 1.08 (0.84-1.40) 0.020 1.10 (0.96-1.26) 0.363 0.98 (0.78-1.24) 0.006 1.06 (0.91-1.23) 0.075
East Asian 6 0.44 (0.08-2.48) 0.000 0.49 (0.11-2.13) 0.000 0.79 (0.46-1.36) 0.000 0.44 (0.09-2.33) 0.000
African 2 1.85 (1.23-2.79) 0.275 1.48 (1.08-2.01) 0.302 1.48 (1.07-2.05) 0.403 1.58 (1.14-2.20) 0.245
Mixed 1 0.91 (0.76-1.09) / 0.92 (0.78-1.08) / 0.97 (0.84-1.12) / 0.92 (0.79-1.06) /
Source of controls          
Hospital 12 0.86 (0.49-1.51) 0.000 0.99 (0.69-1.43) 0.000 0.89 (0.66-1.19) 0.000 0.90 (0.60-1.38) 0.000
Population 6 1.22 (0.84-1.76) 0.000 1.14 (0.86-1.51) 0.000 1.12 (0.90-1.39) 0.001 1.11 (0.84-1.46) 0.000
Sample size in cases          
< 150 6 0.89 (0.37-2.12) 0.014 1.08 (0.55-2.13) 0.046 0.84 (0.51-1.38) 0.040 1.03 (0.53-2.01) 0.034
>=150 12 1.04 (0.75-1.46) 0.000 1.07 (0.85-1.35) 0.000 1.02 (0.84-1.24) 0.000 1.02 (0.80-1.31) 0.000
a Only presented the study with enough detail, one study was included only in the calculation of the dominant model.
b P value of the Q-test for heterogeneity test.
doi: 10.1371/journal.pone.0075135.t003
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Figure 4.  Forest plot for the LEPR Q223R polymorphism (recessive model).  
doi: 10.1371/journal.pone.0075135.g004
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Table 4. LEP and LEPR mRNA expression by the genotypes of SNPs, using data from the HapMap a.
Populations LEP rs7799039 (G2548A) LEPR rs1137101 (Q223R)
 Genotypes No. Mean ± SD Pb Ptrendc Genotypes No. Mean ± SD Pb Ptrendc
CHB GG 4 8.82±0.22  0.913 GG 36 8.70±0.23  0.819
 AG 15 8.66±0.23 0.229  AG 8 8.78±0.22 0.402  
 AA 26 8.73±0.23 0.422  AA 1 8.53 0.468  
 AG/AA 41 8.70±0.23 0.311  AG/AA 9 8.75±0.22 0.575  
JPT d GG 1 8.41  0.653 GG 32 8.52±0.22  0.774
 AG 18 8.51±0.24 0.688  AG 12 8.50±0.15 0.774  
 AA 26 8.53±0.20 0.562  AA 0 - -  
 AG/AA 44 8.52±0.21 0.609  AG/AA 12 8.50±0.15 0.774  
CEU d GG 20 8.53±0.30  0.473 GG 26 8.49±0.27  0.427
 AG 44 8.45±0.24 0.228  AG 44 8.48±0.23 0.902  
 AA 21 8.47±0.25 0.492  AA 19 8.43±0.22 0.421  
 AG/AA 65 8.45±0.24 0.242  AG/AA 63 8.46±0.23 0.674  
YRI d GG 87 8.57±0.24  0.749 GG 31 8.57±0.27  0.698
 AG 2 8.62±0.05 0.749  AG 46 8.59±0.22 0.728  
 AA 0 - -  AA 12 8.51±0.26 0.561  
 AG/AA 2 8.62±0.05 0.749  AG/AA 58 8.57±0.22 0.936  
a Genotyping data and mRNA expression levels for LEP or LEPR by genotypes were obtained from the HapMap phase II release 23 data from EBV-transformed
lymphoblastoid cell lines from 270 individuals, including 45 unrelated Han Chinese in Beijing (CHB).
b Two-side Student’s t test within the stratum.
c P values for the trend test of mRNA expression among three genotypes for each SNP from a general linear model.
d There were missing data because genotyping data for six individuals were not available for LEP and three individuals were not available for LEPR.
doi: 10.1371/journal.pone.0075135.t004
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